Dr Guila Delouya, M.D., M.Sc.

Assistant professor, clinical;
Faculty of medicine, Departement of radiology, radio-oncology;
and nuclear medecine;
Université de Montréal, CRCHUM and Institut du cancer de Montréal.

 

Key words: Microbiota, cancer, inflammation, inflammatory bowel disease (IBD), iron, hereditary hemochromatosis gene (HFE), hepcidin, hemojuvelin, toll-like receptors, major histocompatibility complex I (MHC class I); lipocalin 2 (Lcn2)

2005 Ph.D. Medicine, University of Montreal

2011 Residency in radio-oncology, University of Montreal

2014  M.Sc., Biomedical Sciences,  University of Montreal, Laboratories of Drs Mes-Masson et Rodier.

2008 Prize forbest poster presentation by a resident in radio-oncology at the annual Canadian Association of Radiation Oncology conference (ACRO-CARO)

2009  Recipient of the ‘’Radiation Therapy Oncology Group Travel Award’’ (RTOG), New Orleans, Louisiana

2011 Dean's honor list a th the Université de Montréal

2012  Scholarship ABS/Nucletron joint sponsored HDR Brachytherapy Scholarship program for 2012

2012  Prize for best oral presentation by a resident at the annual Canadian Association of Radiation Oncology conference (ACRO-CARO)

2014  Abbvie CARO Uro-Oncologic Radiation Awards (ACURA). 

2015 Abbvie CARO Uro-Oncologic Radiation Awards (ACURA). 

2015  Best Abstract in clinical and population based oncology. CARO, Kelowna, BC. 

2015  Teaching support-Université de Montreal – Prostate sample biobank for pre and post-treatment samples and data (clinical, socio-demongraphic and biological) for prostate cancer research – pilot study 

2016  Astellas. Co-investigator. 

2016  Donner la Frousse au Cancer's scholarship

  • 2016-17  (PI), Janssen pharmaceutical company of Johnson & Johnson 

    “A new Prostate Cancer biobank to evaluate DNA Damage Responses during Treatment”

The role of DNA damage repair in cancer and the role of cellular senescence in aging and cancer, specifically prostate cancer 

Prostate cancer (PCa) has the highest incidence rate and is the second leading cause of cancer deaths in men after lung cancer. PCa is a major public health problem in North America. Although PCa treatment is often effective, there is still no clear concensus on the factors that can accurately predict the risk of agressive progression. In order to develop personalized treatments for each patient, it is therefore crucial to determine the factors that influence not only the development but also the remission of PCa.

 

To facilitate research in this field, the Institut has a PCa biobank with a rich diversity of biological samples from prostectomy patients. In addition to biological samples, this biobank also contains medical data that has enabled several CRCHUM researchers and their collaborators across Canada to conduct comprehensive studies and make important discoveries in the field of PCa.

 

As a radio-oncologist in the Radio-oncology department of the CHUM, I treat many PCa patients and it is often difficult to find the best treatment option. My research interests as well as those of my collaborators are centered on PCa and how to optimize and personalize its treatment. In order to achieve this, we evaluate the DNA damage response (DDR) in PCa.

 

Inflicting potentially oncogenic DNA lesions triggers a signaling cascade that promotes DNA repair and activation of cell cycle control points to preserve the integrity of the genome.  Recent discoveries suggest that DDR activation may halt cancer in several human pre-neoplastic lesions, including PCa. Our hypothesis is that DDR activation levels vary according to the different grades and aggressiveness of PCa. These levels could be controlled and may predict patients clinical responses to treatments. Furthermore, this research could help define a strategy and new biomarkers to predict treatment outcomes and adapt them accordingly. Our objective is to create a new biobank from PCa patients treated with radiotherapy (a source of DNA damage). This bank will serve to enrich the existing prostate biobank at the CRCHUM.

 

The rationale behind this addition is that patients do not all respond similarly to radiotherapy treatments. The cellular and molecular response to treatment in prostatic tissue could enrich our knowledge and allow us to detect new biomarkers for more efficient stratification of patients (prediction of treatment response).

 

In effect, cancer cells respond to treatment by triggering cascades of complex cellular responses, including survival, death (apoptosis or necrosis) and/or senescence. Cellular senescence is particularly interesting because senescent cells provoke DNA damage, changing the phenotype of secretion, which modulates the interactions between normal cells, tumor cells, endothelial cells and local immune cells.

 

We hope that this biobank will allow us to evaluate if senesence and SASP markers can be detected in tissue and circulationg blood before and after treatment and, in parallel, to conduct ex-vivo studies to better understand molecular pathways of senescence and try to improve this response in tumor cells.

 

We hope to better understand the PCa microenvironment by uncovering new molecular parameters. These parameters may also play a major role in the elimination of tumor cells in vivo and may influence the ability of the treated cancer cells to develop resistance to treatment.

 

The discovery of new biomarkers may eventually be used clinically as part of the patient's profile, which currently includes prostate specific antigen (PSA) levels and Gleason scores, in order to customize and optimize the patients treatment.

 

Current projects (techniques used):

A new Prostate Cancer biobank to evaluate DNA Damage Responses during Treatment

 

Associated websites:

  1. ChUM webpage 

  2. Research gate

  3. Pubmed

     

Pharma Collaborators: 

  • Janssen

 

 

  1. Taussky D, Ouellet V, Guila Delouya G,Saad F. A comparative study of radical prostatectomy and permanent seed brachytherapy for low and intermediate risk prostate cancer. Accepted for publication in Can Urol Assoc J. February 2016.

  2. Lauche O, Delouya G,Taussky D, Menard C, Barkati et al. Single-fraction high-dose rate brachytherapy using real-time transrectal ultrasound based planning in combination with external beam radiotherapy for prostate cancer: Dosimetrics and early clinical results. Journal of Contemporary Brachytherapy. March 2016

  3. Delouya G, KrishnanV, Bahary JP, Larrivée  S, Taussky D : Analysis of the cancer of the prostate risk assessment to predict for biochemical failure after external beam radiotherapy or prostate seed brachytherapy. Urology. 2014 Sep;84(3):629-33. doi: 10.1016/j.urology.2014.05.032

  4. Waters A, Delouya G, Donath D, Lambert C, Larrivée S, Zorn KC, Taussky D: Risk factors for PSA bounce following radiotherapy: outcomes from a multi-modal therapy analysis. Can J Urol. 2014 Dec; 21(6):7548-53

  5. Tétreault-Laflamme A, Zilli T, Meissner A, Larrivée S, Sylvestre MP, Delouya G, Taussky D. The Quadrella : A novel approach to analyzing optimal outcomes after permanent seed prostate brachytherapy.  Radiotherapy and Oncology 2014, Apr;111(1):110-3. doi: 10.1016/j.radonc.2014.01.017. Epub 2014 Feb 20.

  6. Chira C, Delouya G, Gruszczynski N, Donath D, Taussky D. Deferred permanent prostate seed brachytherapy does not affect PSA outcome: results from a large retrospective cohort. Can J Urol. 2013 Dec;20(6):7028-34

  7. Chira C, Taussky D, Gruszczynski N, Meissner A, Larrivée, Carrier JF, David Donath, Delouya G: Unusually high prostate-specific antigen bounce after prostate brachytherapy: Searching for etiologic factors. Brachytherapy. 2013 Nov-Dec;12(6):603-7

  8. Chira C, Delouya G, Larrivée S, Carrier JF, and Taussky D. Prostate volume changes during permanent seed brachytherapy: An analysis of intra-operative variations, predictive factors and clinical implication. Radiation Oncology. 2013 July; 8 (177): Epub 2013 July 9.

  9. Delouya G, Taussky D, Ji CR, Sylvestre MP, Donath D. Relationship between prostate-specific antigen bounce body fat distribution and body mass index in permanent seed brachytherapy for prostate cancer. Brachytherapy. 2012 May-Jun; 11(3): 214-8. Epub 2011 Jun 22

  10. Delouya G, Kaufman G, Sylvestre MP, Nguyen TV, Bahary JP, Taussky D, and Després P.The importance of an exponential PSA decline after external beam radiotherapy for intermediate risk prostate cancer.  Cancer Epidemiol. 2012 Apr; 36(2):e137-141. Epub 2011 Nov 16